A Phase III, Randomized, Open-Label Trial to Evaluate Strategies for Providing Antiretroviral Therapy to Infants Shortly After Primary Infection in a Resource Poor Setting.
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Abacavir (Primary) ; Didanosine (Primary) ; Efavirenz (Primary) ; Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Nevirapine (Primary) ; Zidovudine (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms CHER; CIPRA-SA-2; CIPRA-ZA-2
- 15 Feb 2020 Results (n=579) assessing effect of HIV-exposure and timing of antiretroviral treatment initiation in children living with HIV on antibody persistence and memory responses to Haemophilus influenzae type b and pneumococcal polysaccharide-protein conjugate vaccines from two clinical trials: NCT00099658 and NCT00102960 were published in the Vaccine
- 01 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Aug 2009 Planned number of patients changed from 417 to 451 as reported by ClinicalTrials.gov.